Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and Bevacizumab in Extrapulmonary Neuroendocrine Carcinoma
NCT04705519Phase 2Completed
- Sponsor
- Peking University
- Start
- Jan 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and bevacizumab in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Peking University. Started Jan 2021; status: completed.
02
Drugs
paclitaxelbevacizumab
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT04705519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705519.